Biotech & Pharma
For biopharma teams that need rigorous study methodology, biostatistics and regulatory documentation support — without over-claiming regulator or study outcomes.
Who this is for
Clinical, biometrics and regulatory affairs teams in biotech and pharma organisations preparing evidence packages, protocols, analyses and submission-oriented documentation owned by the client.
Typical problems
- Submission documentation surge with limited writing capacity
- Analysis plans or outputs that are hard to interpret across functions
- Gaps between scientific objectives, endpoints and statistical methods
- Cross-functional narrative that does not hold under review
- Tight timelines for client-owned FDA- or EMA-oriented packages
How we approach biopharma programmes
We align methodology, data interpretation and regulatory writing early so packages stay coherent. Stages follow How we work:
- Discover — programme goals, evidence gaps, stakeholders and constraints
- Frame — scope of statistical, study-design and/or writing support; clear exclusions
- Build — analysis plans, protocol/methodology support, structured regulatory writing
- Harden — consistency checks, review-ready structure, handoff notes
- Hand over — client remains sponsor and decision-maker toward agencies
What we typically deliver
- Biostatistics and analysis planning/execution support as agreed
- Clinical study design and protocol structuring support
- Regulatory writing for client-owned submission and interaction materials
- Coordination across science and RA so the technical story stays consistent
Boundaries
- We do not guarantee study success, ethics outcomes or regulator decisions
- We are not FDA, EMA, a sponsor by default, or a mega-CRO unless a contract defines a specific role
- Do not send PHI or confidential regulatory packs through the public website
Relevant expertise
Biostatistics · Clinical study design · Regulatory support · Selected work
Ready to discuss a programme?
Tell us about your organisation and the type of support you need. Do not send PHI or confidential regulatory packs through the public form.